DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

Phase 2

Recruiting

Conditions: Prostate Cancer
Prostatic Neoplasms

Interventions: Drug: Leuprolide
Drug: Relugolix

First Posted Date: 2023-03-13

Last Posted Date: 2025-04-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 110

Registration Number: NCT05765500

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute at Foxborough, Foxborough, Massachusetts, United States

Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing

Not Applicable

Recruiting

Conditions: Genetic Predisposition to Disease
Genetic Predisposition

Interventions: Behavioral: Nest Platform

First Posted Date: 2023-03-08

Last Posted Date: 2024-12-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 40

Registration Number: NCT05759143

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

High-Intensity Interval Exercise in Young Adult Survivors of Pediatric Brain Tumors: A Pilot Feasibility Study

Not Applicable

Recruiting

Conditions: Pediatric Brain Tumor

Interventions: Behavioral: HIIT Exercise Program
Behavioral: Control Group

First Posted Date: 2023-02-23

Last Posted Date: 2025-02-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT05740839

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

Phase 2

Recruiting

Conditions: Waldenstrom Macroglobulinemia

Interventions: Drug: Pirtobrutinib
Drug: Venetoclax

First Posted Date: 2023-02-21

Last Posted Date: 2025-05-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 42

Registration Number: NCT05734495

Locations: 🇺🇸
Beth Israel Deaconness Medical, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

Phase 2

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma
Head and Neck Cancer
Resectable Head and Neck Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma
Second Primary Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Pembrolizumab
Drug: CISPLATIN
Drug: Carboplatin
Drug: Docetaxel

First Posted Date: 2023-02-13

Last Posted Date: 2025-05-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 28

Registration Number: NCT05726370

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

STOP-HER2: Stopping Trastuzumab in HER2+ MBC

Phase 2

Recruiting

Conditions: Breast Cancer
Metastatic Breast Cancer
HER2-positive Breast Cancer

Interventions: Other: Cessation of anti-HER2 treatment

First Posted Date: 2023-02-09

Last Posted Date: 2024-09-30

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 82

Registration Number: NCT05721248

Locations: 🇺🇸
Mayo Clinic Hospital Arizona, Phoenix, Arizona, United States
🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
Mayo Clinical Hospital Florida, Jacksonville, Florida, United States

and more 10 locations

Patient-Centered Surgical Prehabilitation

Not Applicable

Recruiting

Conditions: Cystectomy
Bladder Cancer

Interventions: Other: Exercise Training
Dietary Supplement: Nutritional Intervention

First Posted Date: 2023-02-08

Last Posted Date: 2023-03-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 25

Registration Number: NCT05715684

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Not Applicable

Recruiting

Conditions: Multiple Myeloma
Stem Cell Transplant Complications

Interventions: Behavioral: PARE
Behavioral: Waitlist Control Group

First Posted Date: 2023-01-31

Last Posted Date: 2025-03-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT05706766

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Novel Intervention for Patients With Cancer

Not Applicable

Recruiting

Conditions: Cancer
Psychological
Substance Use

Interventions: Behavioral: Acceptance and Commitment Therapy

First Posted Date: 2022-12-08

Last Posted Date: 2024-11-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 40

Registration Number: NCT05643027

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)

Not Applicable

Active, not recruiting

Conditions: Breast Cancer
Genitourinary Cancer
Thoracic Cancer
Gastrointestinal Cancer
Gynecologic Cancer

Interventions: Other: Clinician Nudge Email
Other: Patient Nudge Letter and Share questionaire

First Posted Date: 2022-11-29

Last Posted Date: 2024-10-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 800

Registration Number: NCT05629065

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy